Strong cash flow but muted recovery prompt Morgan Stanley downgrade on Evonik stock

Published 11/12/2024, 08:32
Strong cash flow but muted recovery prompt Morgan Stanley downgrade on Evonik stock

On Wednesday, Morgan Stanley (NYSE:MS) shifted its stance on Evonik Industries AG (ETR:EVKn) (EVK:GR) (OTC: EVKIF), moving the chemical company's stock rating from 'Equalweight' to 'Underweight'. The firm also adjusted the price target to €18.60, a decrease from the previous target of €22.00.

The downgrade was influenced by the expectation that Evonik's profit recovery may lag behind its peers despite the company's resilient performance throughout 2024. Morgan Stanley acknowledged the company's robust portfolio, recovery in specific sectors such as methionine and coatings, and strong cash flow generation.

However, the firm pointed out that the share price decline following the third-quarter results of 2024 was seen as excessively severe, and the current valuation is not considered demanding.

Morgan Stanley's analysis suggests that while Evonik has maintained a strong performance, the anticipated macroeconomic improvements in China and Europe might not benefit the company as much as others in the industry.

The factors that previously contributed to Evonik's outperforming shares, including limited exposure to China and a focus on high-value products in Europe, are expected to be overshadowed as investors shift their focus towards companies with higher beta exposure to economic recovery and the effects of stimulus in China.

The firm's revised view reflects a cautious outlook on Evonik's potential for profit growth relative to its competitors, despite the company's solid operational foundation. This adjustment in rating and price target is aimed at aligning expectations with the evolving market dynamics and investment trends observed by Morgan Stanley.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.